We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 46

CETA and Canadian IP law: Possible changes ahead?
  • Gowling WLG
  • Canada, European Union
  • March 3 2016

In 2013, an agreement in principle was reached between Canada and the European Union - theCanada-European Union Comprehensive Economic and Trade


Apotex v Shire, motion to amend statement of defence, modafinil, August 19, 2010
  • Gowling WLG
  • Canada
  • September 21 2010

In an action brought by Apotex for damages pursuant to Section 8 of the PMNOC Regulations against Shire after an unsuccessful PMNOC proceeding brought by Shire, Shire moved to amend the statement of defence


Merck v Apotex, PMNOC proceedings, dorzolamide and timolol, October 22, 2010
  • Gowling WLG
  • Canada
  • November 24 2010

Merck’s patent in this case (the ‘965 patent) covered the co-administration and co-formulation of dorzolamide and timolol (which was sold as COSOPT


Time for change? Potential impact of Canada’s trade negotiations on pharma patents
  • Gowling WLG
  • Canada
  • April 22 2013

Bringing a new drug to market is a costly and time-consuming endeavour. It is a process inherent with the risk of failure. In recognition of this


Methods of medical treatment claims issues in Canada, US and Europe
  • Gowling WLG
  • Canada, European Union, USA
  • November 30 2012

In this presentation, Scott Foster and Konrad Sechley address methods of medical treatment claims issues in Canada, US and Europe


Celgene Corporation v Canada (AG) - Supreme Court of Canada grants leave to appeal
  • Gowling WLG
  • Canada
  • May 21 2010

The Supreme Court of Canada has granted Celgene Corporation's application for leave to appeal the decision of a majority of the Federal Court of Appeal regarding the jurisdiction of the Patented Medicine Prices Review Board


Pfizer v. Novopharm, interlocutory motion in PMNOC Regulations case
  • Gowling WLG
  • Canada
  • May 21 2010

Novopharm served a NOA on Pfizer which it had designated confidential


Astrazeneca v. Apotex, interlocutory motion to strike affidavit in PMNOC Regulations case
  • Gowling WLG
  • Canada
  • May 21 2010

This was an appeal to the Federal Court of Appeal (FCA) of the decision of Justice Hughes refusing to strike an affidavit from the record


Janssen-Ortho v. Apotex, recusal by the judge, levofloxacin, June 14, 2010; motion to dismiss granted, levofloxacin, June 29, 2010
  • Gowling WLG
  • Canada
  • July 16 2010

In a PMNOC case, Justice Shore granted an order of prohibition against Apotex in respect of its levofloxacin until patent expiry


Pfizer v Ratiopharm, PMNOC Regulations decision, sildenafil citrate, June 8, 2010
  • Gowling WLG
  • Canada
  • July 16 2010

The Court dismissed an application for an order of prohibition under the PMNOC Regulations, wherein ratiopharm sought a generic version of the drug Revatio containing sildenafil citrate (the active ingredient in Viagra) until after the expiry of a Pfizer patent